Benzinga · Mar 6, 2026
TV
NASDAQ · TVGNW
Tevogen Bio Holdings Inc.
Healthcare · Biotechnology
$0.09
Up+$0.01 (+7.95%)
Updated Nov 5, 2026, 2:57 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 9.25M
- P/E ratio
- -2.7
- Dividend yield
- 0.00%
- 52-week range
- $0.03 – $0.12
- Volume
- 307.34K
- Avg. volume
- 111.92K
Price performance · TVGNW
TVGNW price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
TVGNW closed at $0.09 after 21 trading sessions, up 24.71% for the selected period.
- Last close
- $0.09
- Period change
- +24.71%
- Period low
- $0.06
- Period high
- $0.09
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $0.0875 | $0.0999 | $0.0822 | $0.0868 | 307.34K |
| Nov 3, 2026 | $0.0938 | $0.10 | $0.0767 | $0.0767 | 420.62K |
| Nov 2, 2026 | $0.089 | $0.0999 | $0.076 | $0.0783 | 422.79K |
| Oct 30, 2026 | $0.0908 | $0.0975 | $0.0751 | $0.0875 | 627.93K |
| Oct 29, 2026 | $0.09 | $0.0975 | $0.0717 | $0.074 | 808.24K |
| Oct 28, 2026 | $0.0825 | $0.1175 | $0.0706 | $0.0845 | 894.97K |
| Oct 27, 2026 | $0.073 | $0.09 | $0.065 | $0.0804 | 934.52K |
| Oct 26, 2026 | $0.0689 | $0.0774 | $0.064 | $0.0728 | 660.81K |
| Oct 23, 2026 | $0.0636 | $0.0689 | $0.0606 | $0.0672 | 562.97K |
| Oct 22, 2026 | $0.063 | $0.0689 | $0.0608 | $0.065 | 680.94K |
| Oct 21, 2026 | $0.0615 | $0.0687 | $0.0602 | $0.0648 | 836.13K |
| Oct 20, 2026 | $0.0602 | $0.0678 | $0.055 | $0.063 | 534.89K |
| Oct 19, 2026 | $0.0655 | $0.0683 | $0.0421 | $0.0636 | 752.01K |
| Oct 16, 2026 | $0.0683 | $0.0689 | $0.0599 | $0.0689 | 113.48K |
| Oct 15, 2026 | $0.07 | $0.07 | $0.0685 | $0.07 | 9.31K |
| Oct 14, 2026 | $0.0725 | $0.0784 | $0.0657 | $0.0698 | 158.61K |
| Oct 13, 2026 | $0.07 | $0.0787 | $0.065 | $0.0787 | 204.87K |
| Oct 12, 2026 | $0.0743 | $0.078 | $0.0633 | $0.0699 | 210.81K |
| Oct 9, 2026 | $0.0715 | $0.0795 | $0.0615 | $0.0697 | 316.96K |
| Oct 8, 2026 | $0.075 | $0.08 | $0.0651 | $0.0715 | 447.54K |
| Oct 7, 2026 | $0.0631 | $0.075 | $0.0588 | $0.0696 | 500.44K |
Latest TVGNW news
The latest Smart Investors Daily articles mentioning TVGNW.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TVGNW research
Overview
Company profile and research snapshot.
Company profile
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Dec 8, 2025
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
Tevogen Bio was recognized by NJBIZ for its innovative ExacTcell™ platform and AI technology, with projected near-term commercial potential of $1 billion in first-year revenue and a five-year forecast of $18-22 billion.
Yahoo · Nov 14, 2025
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
WARREN, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced the filing of its quarterly report on Form 10-Q for the quarter ended September 30, 2025, highlighting continued capital-efficient execution at a time when sustainability has become what the Company believes a defining challenge for the biotechnology industry. Tevogen reported a loss from operations calculated in accordance with U.S. GAAP of $5.7 million for the thre
GlobeNewswire Inc. · Nov 3, 2025
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
Tevogen Bio explains its accumulated deficit of $129 million, highlighting that the majority represents non-cash expenses and is offset by additional paid-in capital, with total cash loss under $42 million.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
